Luther Medical/MedChem
This article was originally published in The Gray Sheet
Executive Summary
Catheter systems manufacturer Luther Medical receives acquisition offer from MedChem Products. According to Luther, MedChem is opening negotiations "with a valuation range of $3.50- 4 per share, payable in cash and/or MedChem common stock," making the deal worth $10-11.5 mil. On Sept. 15, the day of the MedChem offer, Luther stock closed at $2.875 per share. Commenting on the offer, Luther President and CEO David Rollo says that the company's board "will meet soon to consider the MedChem proposal seriously"
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.